Lead
No new developments reported.
Neither source provides new financial data or events to report.
No new developments reported.
Recommended on Amazon
Affiliate links — we may earn a commission at no extra cost to you.
Cellectar Therapeutics plans to begin Phase III trials in late 2026, with a potential FDA approval window in the second half of 2027. The company’s schedule aligns with its clinical development pipeline and regulatory strategy.
PenFed’s 2026 review shows strong membership growth and expanded services, positioning it as a top choice for military personnel. The review outlines key benefits and future plans for the credit union.
Tickets for the 2026 World Cup have surged to $10,000, while a former summer intern now heads Target’s revitalization. Both stories highlight extreme price points in sports and retail.